The CURE: Digestive Diseases Research Core Center (CURE: DDRCC) is composed of a cohesive group of physicians and basic scientists with strong independent peer-reviewed grant-supported research programs in the biology of the gut, with special emphasis upon regulation of mucosal cell function, gut neuroscience and signal transduction mechanisms. CURE, created in 1974, has grown and evolved into a broadly based gastrointestinal research organization with multiple affiliations, principally the VA and UCLA. Since 1989, a fundamental component of CURE has been the NIDDK-supported CURE: DDRCC. The research emphasis of the Center is acquisition of new knowledge about molecular, cellular and physiological processes that control gastrointestinal function and translation of this knowledge into development of therapy for patients with gastrointestinal diseases. The research programs of the CURE: DDRCC members can be broadly divided into four major areas: (1) gastroduodenal mucosal physiology and disease; (2) intestinal and pancreatic physiology and disease; (3) neural regulation of gastroenteric function and neuroenteric disease; and (4) mechanism of action of gastrointestinal peptides, including receptor regulation, signal transduction and control of cell proliferation. The Biomedical Research Cores outlined in this proposal provide ready access to technologies, and to clinical and biological materials that are essential to the programs of center members. These Cores provide access to modem cellular imaging to study signaling proteins and their functions, animal models for studying physiology and pathophysiology, and access to a broad range of techniques and patients for clinical studies. New services incorporated in this proposal include proteomics, GI cell biology, functional genomics, signal transduction and development of gene transfer vectors. The Administrative Core provides a wide range of administrative support for members and for center activities including a dynamic enrichment program. The Pilot and Feasibility and the Named New Investigator Programs have provided successful mechanisms for aiding the development of new research programs in gastrointestinal biology by young investigators. The center provides an optimal environment for cooperation and collaboration among its investigators, who have had a major impact on digestive disease research over the past three decades and promise to have an even larger impact upon expanded research areas with continued support from the Center.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK041301-18
Application #
7172660
Study Section
Special Emphasis Panel (ZDK1-GRB-6 (M1))
Program Officer
Podskalny, Judith M,
Project Start
1996-12-01
Project End
2009-11-30
Budget Start
2006-12-01
Budget End
2007-11-30
Support Year
18
Fiscal Year
2007
Total Cost
$770,631
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Hoffman, Jill M; Sideri, Aristea; Ruiz, Jonathan J et al. (2018) Mesenteric Adipose-derived Stromal Cells From Crohn's Disease Patients Induce Protective Effects in Colonic Epithelial Cells and Mice With Colitis. Cell Mol Gastroenterol Hepatol 6:1-16
Bonfiglio, Ferdinando; Zheng, Tenghao; Garcia-Etxebarria, Koldo et al. (2018) Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. Gastroenterology 155:168-179
Wen, Yi; Scott, David R; Vagin, Olga et al. (2018) Measurement of Internal pH in Helicobacter pylori by Using Green Fluorescent Protein Fluorimetry. J Bacteriol 200:
Kageyama, Shoichi; Nakamura, Kojiro; Fujii, Takehiro et al. (2018) Recombinant relaxin protects liver transplants from ischemia damage by hepatocyte glucocorticoid receptor: From bench-to-bedside. Hepatology 68:258-273
Wang, Jiani; Ghali, Sally; Xu, Chunlan et al. (2018) Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites. Gastroenterology 154:1737-1750
Koon, Hon Wai; Wang, Jiani; Mussatto, Caroline C et al. (2018) Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-?B Activity. Antimicrob Agents Chemother 62:
Rankin, Carl Robert; Theodorou, Evangelos; Man Law, Ivy Ka et al. (2018) Identification of novel mRNAs and lncRNAs associated with mouse experimental colitis and human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 315:G722-G733
Manatsathit, Wuttiporn; Khrucharoen, Usah; Jensen, Dennis M et al. (2018) Laparotomy and intraoperative enteroscopy for obscure gastrointestinal bleeding before and after the era of video capsule endoscopy and deep enteroscopy: A tertiary center experience. Am J Surg 215:603-609
Dong, Tien; Pisegna, Joseph (2018) Passing the ""Acid Test"": Do Proton Pump Inhibitors Affect the Composition of the Microbiome? Dig Dis Sci :
Park, S H; Naliboff, B D; Shih, W et al. (2018) Resilience is decreased in irritable bowel syndrome and associated with symptoms and cortisol response. Neurogastroenterol Motil 30:

Showing the most recent 10 out of 1097 publications